Miromatrix Medical stock soars after it agrees to be bought by United Therapeutics
Miromatrix Medical Inc.'s stock (MIRO) jumped 230% in premarket trades on Monday after the company agreed to be acquired by United Therapeutics Corp. (UTHR) for $3.25 per share in cash, or about $91 million. The deal also includes a milestone payment of $1.75 per share in cash upon the achievement of clinical development of Miromatrix's development-stage, fully-implantable manufactured kidney product, Mirokidney by Dec. 31, 2025. The price of $3.25 a share amounts to a premium of approximately 170% to the 30-day volume-weighted average trading price of Miromatrix's common stock as of Friday. Miromatrix's board has recommended that Miromatrix's stockholders agree to the offer. The deal is expected to close in the fourth quarter. United Therapeutics's stock is down 21% so far in 2023, compared to a 20.8% rise by the Nasdaq .
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
10-30-23 0623ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations